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The E3 ubiquitin ligase SMURF1 
regulates cell-fate specification 
and outflow tract septation during 
mammalian heart development
K. Koefoed1, J. Skat-Rørdam1, P. Andersen2, C. B. Warzecha3, M. Pye4, T. A. Andersen1,  
K. D. Ajbro1, E. Bendsen5, M. Narimatsu4, F. Vilhardt1, L. B. Pedersen  3, J. L. Wrana4,  
R. H. Anderson6, K. Møllgård  1, S. T. Christensen 3 & L. A. Larsen  1
Smad ubiquitin regulatory factor 1 (SMURF1) is a HECT-type E3 ubiquitin ligase that plays a critical role 
in vertebrate development by regulating planar cell polarity (PCP) signaling and convergent extension 
(CE). Here we show that SMURF1 is involved in mammalian heart development. We find that SMURF1 
is highly expressed in outflow tract cushion mesenchyme and Smurf1−/− mouse embryos show delayed 
outflow tract septation. SMURF1 is expressed in smooth muscle cells of the coronary arteries and great 
vessels. Thickness of the aortic smooth muscle cell layer is reduced in Smurf1−/− mouse embryos. We 
show that SMURF1 is a negative regulator of cardiomyogenesis and a positive regulator of smooth 
muscle cell and cardiac fibroblast differentiation, indicating that SMURF1 is important for cell-type 
specification during heart development. Finally, we provide evidence that SMURF1 localizes at the 
primary cilium where it may regulate bone morphogenetic protein (BMP) signaling, which controls the 
initial phase of cardiomyocyte differentiation. In summary, our results demonstrate that SMURF1 is a 
critical regulator of outflow tract septation and cell-type specification during heart development, and 
that these effects may in part be mediated via control of cilium-associated BMP signaling.
Heart development is a complex process involving different cell types as well as different types of cell movements. 
At least three different cell sources contribute to heart development, including cells from first and secondary heart 
field (FHF and SHF, respectively), cardiac neural crest cells (CNC) and cells from the proepicardial organ (PEO). 
The process of endothelial to mesenchymal transition (EndoMT) is important for cardiac septation in the atrio-
ventricular canal (AVC) and outflow tract (OFT). In the mouse, at the onset of OFT septation (E10.5), the cardiac 
tube consists of an outer myocardial and an inner endocardial layer separated by a layer of extracellular matrix 
(cardiac jelly)1,2. As endocardium-derived mesenchymal cells begin to invade the cardiac jelly by EndoMT in the 
proximal OFT cushions, CNC cells de-laminate by convergent extension (CE) to migrate through the pharyngeal 
arches to populate the distal part of the OFT to participate in formation of the aortopulmonary septum, and also 
enter the major outflow cushions3–7. By E12.5, the aortopulmonary septum has fused with the distal end of the 
outflow cushions, and septation of the OFT is completed8.
SMURF1 is a HECT-type E3 ubiquitin ligase, which predominantly patterns ectodermal tissues. Aberrant 
expression of the protein results in ectodermal-derived defects such as neural tube closure defects9–11. Mice 
with loss of Smurf1 expression are vital and fertile with no apparent developmental defects12. Double knockout 
mouse embryos lacking SMURF1 and the homologous protein, SMURF2, however, die prenatally around E10.5. 
They present with neural tube closure defects, reminiscent of phenotypes seen in morphant Smurf1 Xenopus and 
zebrafish embryos9,11,13,14. Loss of three of four Smurf alleles in mice, with one Smurf1 allele remaining, results in 
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defects similar to the Smurf1/2 double knockout mice, although the mice survive gestation13. This suggests that 
there is some degree of redundancy between SMURF1 and SMURF2, which correlates well with the proteins 
being co-expressed in e.g. pharyngeal arches and ectodermal structures in Xenopus embryos15. The phenotypes 
observed in Smurf1/2 double knockout mice suggest that SMURF proteins are involved in regulation of planar 
cell polarity (PCP) signaling and CE during development13. In support of a role in regulating CE, previous studies 
indicated a role for SMURF1 in regulating cell polarity, cell migration and EMT through local ubiquitination of 
the small GTPase RHOA at cellular protrusions16–19. Several studies have pointed to a role of SMURF proteins in 
cardiovascular development. For example, Smurf1 and 2 are highly expressed in the mouse embryonic heart13. 
SMURF1 is involved in EndoMT processes in chicken AVC explants and in mouse epicardial cells18,20. Previously, 
a 480 kbp de novo duplication including SMURF1 was identified in a screen for copy number variants in a cohort 
of patient with congenital heart defects (CHD)21 and a de novo frameshift mutation in SMURF1 was recently 
associated with left-sided CHD22. The precise function of SMURF proteins in heart development, nonetheless, 
remains poorly understood.
At the molecular level, SMURF proteins have been implicated in the positive and negative regulation of numer-
ous cellular and developmentally important signaling pathways, including canonical TGFβ/BMP signaling as well 
as WNT/PCP signaling, TGFβ/PAR6/RHOA, Hedgehog, Hippo and NF-κB signaling9,12,13,16–19,23–27. The majority 
of these pathways are known to be coordinated, at least in part, by the primary cilium - a microtubule-based 
signaling organelle that emerges from the surface of many different cell types in the body depending on their cell 
cycle and differentiation status28–34. In this context, it is noteworthy that SMURF1 and 2 were shown recently to 
promote activation of Sonic hedgehog (Shh) signaling by mediating the ubiquitination and endocytic clearance 
of the Shh receptor Patched1 from the ciliary compartment24. In addition, SMURF1 was reported to function as 
a negative regulator of TGFβ/BMP signaling in developing Xenopus embryos by targeting SMAD transcription 
factors and receptors for degradation9,23,35,36. SMAD-mediated TGFβ/BMP signaling has also shown to be asso-
ciated with the primary cilium37–41, for example during differentiation of mouse carcinoma stem cells (P19.CL6 
cells) into cardiomyocytes where TGFβ-mediated phosphorylation of SMAD2/3 at the ciliary base is required for 
the process of cardiomyogenesis40. Despite these findings, the potential link between SMURF proteins and the 
primary cilium remains unclear.
In this study, we used human embryonic hearts, as well as wild type and mutant mouse embryos and stem 
cell models, to address the role of SMURF1 during heart development, and to examine the mechanisms involved. 
Using these approaches, we demonstrate that SMURF1 regulates OFT septation and cell-type specification during 
heart development by a mechanism that may involve SMURF1-mediated regulation of cilium-associated BMP 
signaling. These results provide important new insight into the process of OFT septation and the mechanisms that 
define cell-type specifications during cardiac development, in turn paving the way for improved in vitro differen-
tiation of cardiomyocyte subtypes for use in treatment of cardiovascular diseases.
Results
SMURF1 is expressed in a spatiotemporal manner during human heart development. To 
investigate the expression pattern of SMURF1 during human heart development, we first analyzed the relative 
SMURF1 mRNA levels of 20 human embryonic hearts, ranging from 39–68 days post fertilization (dpf), as well as 
three adult hearts, by quantitative reverse transcriptase (qRT)-PCR. This analysis showed that SMURF1 expres-
sion is about 12-fold higher in 39–44 dpf embryonic hearts compared to adult hearts (Fig. 1A). Next, we examined 
the spatial expression pattern of SMURF1 in similar samples using immunohistochemistry (IHC). In 35–38 dpf 
embryonic hearts, SMURF1 is expressed in the myocardium and OFT cushions, with a particular strong expres-
sion in the latter (Fig. 1B and C). We also observed a variation in the subcellular localization of SMURF1 in differ-
ent cell types, with SMURF1 predominantly localizing to the nucleus in cells in the endocardium of the ventricle 
and OFT (closed arrowheads in Fig. 1b’). Cardiomyocytes of the ventricle and atria, in contrast, display SMURF1 
localization also in the cytoplasm (open arrowheads Fig. 1b”). In the myocardium of the OFT, the localization 
appears equally intense in the cytoplasm and nuclei (red arrowhead). At 35 dpf, SMURF1 is localized preferen-
tially at the plasma membrane in the mesenchymal cells of the OFT cushions, as well as in the AVC (open arrows 
in 1b’ and Suppl. Fig. 1).
The expression of SMURF1 in the AVC cushions appears to be transient, since these cushions are negative 
for SMURF1 at 38 dpf. By this stage, in contrast, the expression is enriched in the OFT (Fig. 1C). SMURF1 is 
expressed in both OFT cushions (Fig. 1C and Suppl. Fig. 2), with a more prominent expression distally. The 
confocal image (from a neighboring section) in Fig. 1c” shows that SMURF1 is highly expressed in the mesen-
chymal cells, compared to the myocardium (marked by TBX2), and that SMURF1 expression is continuously 
abundant at cell membranes in the cushion mesenchyme (Fig. 1c”’). As heart development progresses, the expres-
sion of SMURF1 in the myocardium is lost, becoming restricted to more confined areas (Fig. 1D–F). At 40 dpf, 
SMURF1 is expressed in the CNC-derived condensed mesenchyme between the developing aortic root and the 
infundibulum of the pulmonary trunk (red outline in Fig. 1D), suggesting that SMURF1 may be involved in 
CNC-mediated septation of the OFT. At the coronary sinus, SMURF1 is expressed in a pattern reminiscent of a 
role in specifying the endothelium of the coronary artery (green outline in 1D)42–44. This pattern is also evident 
in a neighboring section in the 38 dpf heart (Suppl. Fig. 2). At 40 dpf SMURF1 is also expressed in the infundib-
ulum and the proximal aorta, and in the pulmonary trunk. When the heart is fully septated at 49 dpf, SMURF1 
expression is maintained in the infundibulum and the pulmonary trunk, as well as in the remnants of the con-
densed CNC mesenchyme (arrowheads in Fig. 1E). At 49 and 55 dpf, SMURF1 also marks the smooth muscle 
cells (SMCs) in the developing coronary arteries (black arrow in Fig. 1E,F). Additionally, at 55 dpf the atrioven-
tricular node (AVN) is SMURF1-positive, whereas the sinus node remains SMURF1 negative (asterisk in 1F). At 
70 dpf, SMURF1 expression appears stronger in the right ventricle (RV) compared to the left ventricle. This might 
suggest a specific role in the RV. By this time, expression in SMCs is lost in the great vessels and coronary arteries 
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Figure 1. Expression of SMURF1 during human heart development. (A) SMURF1 expression in human 
embryonic, fetal and adult hearts. Expression level was examined using qRT-PCR and normalized to average 
values of three housekeeping genes (GAPDH, COX4 and ATP6). Expression level is shown as fold change 
compared to expression in the adult heart. Variations between groups were compared using a one-way ANOVA. 
*p < 0.05, ***p < 0.001, ****p < 0.0001. (B) IHC staining of SMURF1 in a human heart section from 35 dpf. b’ 
and b” enlargement of boxes indicated in B; closed arrow heads show endothelial cells, open arrow heads show 
membrane localization and red arrow shows nuclear localization (see Supplemental Fig. 1 for enlargement). 
(C) IHC staining of SMURF1 in a human embryonic heart section from 38 dpf. c’ Enlargement of the boxed 
area in C. c” IF-IHC image of a neighboring section in the area marked by the box in C (SMURF1 (red), 
TBX2 (green); nuclei are stained with DAPI (blue). c”’ enlargement of box indicated in c”. (D) IHC staining of 
SMURF1 in a human embryonic heart from 40 dpf. Red outline: condensed CNC mesenchyme, green outline: 
patches of SMURF1 positive cells in the coronary sinus. Asterisk indicates the primary atrial septum. (E) 
SMURF1 staining in human embryonic heart from 49 dpf. Closed arrow heads show remnants of condensed 
CNC-derived mesenchyme, open arrow head marks the coronary vessel. (F) SMURF1 staining in human 
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(arrows in 1G). Together, these results suggest that SMURF1 may be involved in OFT septation, and in develop-
ment of SHF-derived structures as well as the coronary arteries and AVN.
OFT septation is delayed and the aortic SMC layer is reduced in Smurf1−/− mouse embryos. Mice 
with targeted deletion in Smurf1 were reported to be viable with no cardiac defects13. Nevertheless, the strong 
expression of SMURF1 in the OFT in human embryonic hearts prompted us to re-examine the OFT in mouse 
Smurf1−/− embryos. We analyzed hematoxylin stained tissue sections from wild type (WT) and homozygous 
Smurf1−/− mice at E12.5 and E15.5. The mice were of the same background as previously published13. As 
expected, the OFT was septated at E12.5 in WT mice (n = 8) (Fig. 2A). In contrast, six out of eight Smurf1−/− 
embryos presented with a common OFT at E12.5. By E15.5, both WT and Smurf1−/− mice presented with a 
fully septated OFT (Fig. 2B), indicating that loss of Smurf1 causes a delay in OFT septation. We observed strong 
expression of SMURF1 in SMC in the developing coronary arteries of human embryos, which might indicate 
a role in development of arterial tissues. This observation encouraged us to analyze the expression of the SMC 
marker alpha-actin-2 (α-SMA) in the aorta of Smurf1 WT and Smurf1−/− mice by IHC. In E15.5 mice, the thick-
ness of the aortic SMC layer was significantly reduced in the Smurf1−/− mice compared to the Smurf1 WT mice 
(Fig. 2C,D), suggesting that SMURF1 is required for proper SMC differentiation.
Loss of Smurf1 increases the rate of cardiomyogenesis in P19.CL6 cells. Based on our findings 
that SMURF1 is expressed in the myocardium of human embryonic hearts, we next investigated the function of 
SMURF1 in cardiomyogenesis. We used the P19.CL6 cell line, which differentiates into cardiomyocytes upon 
addition of 1% DMSO to the culture medium34,40,45. When seeded at a density of 4,000 cells/cm2, the cells dif-
ferentiated as expected into cardiomyocytes within eight to ten days, as judged by the formation of spontaneous 
contracting clusters concomitantly with a loss of Sox2 expression and increased expression of cardiomyocyte 
markers Gata4, Nkx2-5 and α-actinin (Suppl. Fig. 3). Relative expression levels of Smurf1 and Smurf2 were largely 
constant throughout cardiomyogenesis in this assay (Suppl. Fig. 3).
Next, to characterize the function of SMURF1 during cardiomyogenesis in P19.CL6 cells, we used 
CRISPR-Cas9 genome editing to generate stable clones with a 49 bp deletion in exon three of the Smurf1 gene 
(Suppl. Fig. 4A). We randomly selected three clones with wildtype Smurf1 sequence as controls (designated WT 
in the following), and seven homozygous mutants (designated KO) for further analyses. All ten cell clones were 
tested by Sanger sequencing and western blot (WB) analysis to ensure that they were either WT or KO with the 
expected deletion. Figure 3A shows representative examples of results from PCR and WB analyses of a WT clone 
and a homozygous mutant with the top panel displaying PCR products spanning the site of mutation and the 
bottom panel showing a WB where the SMURF1 protein band is missing in the KO, verifying that the mutation 
results in depletion of SMURF1 protein. The ten isolated clones were subjected to cardiac differentiation, and 
the expression level of Gata4 was analyzed at day four as a measure of differentiation stage (Suppl. Fig. 4D). The 
results suggest that the KO mutants display an increased rate of differentiation as compared to the WT clones. 
Two KO mutants (KO#1 and KO#2) and two controls (WT#A and WT#B) were chosen for further analysis 
(Suppl. Fig. 4E). All differentiation experiments were carried out with these four clones, and as shown in Suppl. 
Fig. 4F, the two WT clones displayed a similar level of Gata4 and α-actinin expression at days 4 and 12 of differ-
entiation, respectively, whereas the two KO clones display a significant increase in the expression of Gata4 and 
α-actinin compared to the WT clones. For simplicity, the results represented in the main figures only include 
WT#A and KO#1, which are designated WT and KO, respectively.
In zebrafish, it has been reported that morphants behave differently than mutants because the mutants adapt 
to the mutation by adjusting the transcriptome46. Similarly, Smurf2 was reported to be significantly upregulated 
in the Smurf1−/− mouse, indicating that the mutant mice compensate by increasing Smurf2 transcription13. We 
therefore investigated whether the KO cells had compensated for the loss of SMURF1 by up-regulating expression 
of Smurf2. However, Smurf2 mRNA levels were not significantly different on days 0 and 4 in the KO versus WT 
cells, as assessed by qRT-PCR analysis (Suppl. Fig. 4G). We analyzed the relative expression Sox2 mRNA and the 
cardiomyocyte markers Gata4, Nkx2-5 and α-actinin at days 0, 4 and 12 of differentiation to compare the differ-
entiation dynamics between WT and KO cells. We did not observe any difference in Sox2 expression, indicating 
that the cells leave their pluripotent state at a similar time point after addition of DMSO (Fig. 3B). In line with 
the initial analysis (Suppl. Fig. 4D), the mRNA levels of Gata4 at day 4 and Nkx2.5 and α-actinin at day 12 were 
5–10 times higher in KO cells compared to WT cells (Fig. 3C). In support of these findings, WB analysis showed 
that KO cells express GATA4 at a significantly higher level than that observed in WT cells at days 3 and 7 of dif-
ferentiation (Fig. 3D,E), which coincides with an increased number of cells positive for GATA4 as judged by IFM 
analysis (Fig. 3F). Furthermore, we analyzed the expression of α-actinin using flow cytometry in order to com-
pare the fraction of cells differentiated into functional cardiomyocytes at day 12. Both the mean and the median 
of relative fluorescent light units was higher in the KO culture compared to the WT culture (Fig. 3G), reflecting 
that a significantly larger proportion of cells in the KO culture expresses a high level of α-actinin compared to the 
embryonic heart from 55 dpf. Asterisk marks area of sinus atrial node and open arrows mark coronary vessels. 
f ’ IF-IHC of SMURF1 in a neighboring section showing SMURF1 expression (red) in an the boxed area in F. 
(G) SMURF1 staining in human embryonic heart from 70 dpf. Arrows mark SMC-positive areas. Abbreviations: 
A: Atrium, Ao: Aorta, AoR: Aortic root, AVN: Atrioventricular node, CS: Coronary sinus, Inf: Infundibulum, 
LA: Left atrium, LSCV: Left superior caval vein, LV: Left ventricle, OFT: Outflow tract, PC: Parietal cushion, 
Pt: Pulmonary trunk, RA: right atrium, RV: Right ventricle, SC: Septal cushion, SVC: Superior vena cava, TCV: 
Tricuspid valves, V: Ventricle.
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WT culture. This is also evident from the density plots displayed in Fig. 3H. We transfected both WT and KO cells 
with either a mock or a Smurf1-expressing plasmid to see if we could rescue the phenotype. As shown in Fig. 3I, 
introduction of a transient increase in Smurf1 expression in the KO cells at day 3 of differentiation resulted in 
a slight but significant decrease in Gata4 expression. The same tendency was seen when Smurf1 was transiently 
over-expressed in WT cells (Fig. 3I). Taken together, our results suggest that SMURF1 inhibits cardiomyogenesis 
in P19.CL6 cells.
Depletion of Smurf1 affects the formation of mESC-derived SHF cells. The role of SMURF1 as 
a negative regulator of cardiomyogenesis was further investigated in mouse embryonic stem cells (mESC). We 
used a mESC line which expresses GFP and RFP when the cells differentiate into FHF (GFP+) and SHF (RFP+) 
derivatives, respectively47. These cells were analyzed for their ability to differentiate into cardiomyocytes, vascu-
lar endothelial cells (VEC), SMC cells and cardiac fibroblasts upon siRNA induced Smurf1 depletion. After an 
initial differentiation period of five days the RFP+ and GFP+ cells were FACS-sorted into two pools. Cells were 
Figure 2. Cardiac anatomy in wildtype and Smurf1−/− mice. (A) Hematoxylin stained mice hearts fixed at 
E12.5. Top panel shows wildtype, middle and bottom panel shows Smurf1−/− mice. Outflow track cushions are 
shown with arrows. (B) Hematoxylin stained mice hearts fixed at E15.5. Top panel shows wildtype and bottom 
panel shows Smurf1−/− mice. Abbreviations: A: Atrium, Ao: Aorta, LA: Left atrium, OFT: Outflow tract, PT: 
Pulmonary trunk, RA: Right atrium, RV: Right ventricle, V: Ventricle. (C) IHC staining of α-SMA expression in 
the aorta of E15.5 mice embryos from WT and Smurf1−/− mice. The images are representative of three different 
WT mice and three different Smurf1−/− mice. (D) Quantification of the average thickness of the SMC layer in 
the aorta. N = 3 (one section per mouse). An unpaired t-test was used to for statistical analysis **p < 0.01.
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treated with siRNA against Smurf1 and allowed to differentiate for additional 72 hours followed by RNA isola-
tion and qRT-PCR analysis. The cells were analyzed for expression of the cardiomyocyte marker cardiac muscle 
troponin T (TnnT2), the SMC marker Transgelin (Tagln), the VEC marker kinase insert domain receptor (Kdr), 
Figure 3. Functional analysis of SMURF1 during cardiomyogenesis in P19.CL6 cells. (A) Agarose gel (top 
panel) and WB (bottom panel) of the WT and KO clones used in the experiments. SMURF1 and unspecific (us) 
band in WB is marked with arrows. (B) qRT-PCR analysis of Sox2 expression on before (day 0) and after DMSO 
stimulation (day 4) in WT and KO cells. Data are normalized to Gapdh and Psmd4. Ratio paired t-test was used 
for statistical analysis, n = 10. (C) qRT-PCR analysis of Gata4 expression on day 4 of DMSO stimulation and 
Nkx2-5 and α-actinin on day 12 of DMSO stimulation. Data are normalized to Gapdh and Psmd4. Ratio paired 
t-test was used for statistical analyzes *p < 0.05 **p < 0.01****p < 0.0001, n = 10 for Gata4, and n = 8 for Nkx2-
5 and α-actinin. (D) WB analysis of GATA4 expression during differentiation in WT and KO cells. p150glued was 
used as a loading control. The WB showed is representative of three experiments. (E) Quantification of GATA4 
protein expression during differentiation. Paired t-test was used for statistical analyses, *p < 0.05, **p < 0.01, 
n = 3. (F) Immunofluorescence and Differential interference contrast (DIC) microscopy analysis of WT and KO 
cells on day 3 of DMSO stimulation. GATA4 (red). Nuclei were stained with DAPI (blue). (G) Flow cytometry 
analysis of α-actinin on day 12 of DMSO stimulation in KO and WT cells. Graphs depict the mean and median 
of the Relative Fluorescent Light Units with α-actinin antibody. Paired t-test was used for statistical analyses 
*p < 0.05, ***p < 0.001, n = 6. (H) Density plot of a representative flow cytometry experiment with WT and 
KO cells. (I) qRT-PCR analysis of Gata4 mRNA expression on day 3 of DMSO stimulation in WT and KO cells 
treated with either a Mock or Smurf1 expressing plasmid. Data are normalized to Gapdh and Psmd4. A ratio 
paired t-test was used to for statistical analysis *p < 0.05, **p < 0.01. Original pictures of western blots and the 
agarose gel are shown in Supplemental Fig. 5.
www.nature.com/scientificreports/
7SCIeNTIFIC REPORTs |  (2018) 8:9542  | DOI:10.1038/s41598-018-27854-8
and the cardiac fibroblast marker S100 calcium-binding protein A4 (S100A4) (Fig. 4). The expression of TnnT2 
was not affected by Smurf1 knockdown in FHF cells, however in SHF cells Smurf1 depletion resulted in a signif-
icant increase of TnnT2 expression (Fig. 4A) reminiscent of what we observed in P19.CL6 cells. Interestingly, the 
increase in TnnT2 expression in SHF cells seems to be on behalf of cardiac fibroblasts (Fig. 4C). In FHF cells, there 
is also a significant reduction of cardiac fibroblasts, suggesting that SMURF1 in general is a positive regulator of 
cardiac fibroblasts. The fact that a phenotype is only observed in SHF cells suggests that SMURF1 may regulate 
cell-type specification during cardiomyogenesis in SHF derived structures of the heart. Further, the reduced 
expression of S100A4 suggests that SMURF1 may be a positive regulator of cardiac fibroblasts.
SMURF1 localizes to the primary cilium and regulates BMP signaling in vitro and in vivo. Multiple 
signaling pathways known to be regulated by SMURF1, play a critical role in heart development, including TGFβ/
BMP signaling34 which previously was shown to be coordinated by the primary cilium to promote the differentia-
tion of P19.CL6 cells into cardiomyocytes33,40. To address the role of SMURF1 in regulating BMP signaling during 
cardiomyogenesis, we initially monitored the level of SMAD1/5 phosphorylation during cardiomyogenesis in WT 
and KO P19.CL6 cells by WB analysis. As shown in Fig. 5A, the level of phosphorylated SMAD1/5 (p-SMAD1/5) 
is increased from day 3 of differentiation, which may indicate that SMAD1/5 activation is required for cardiomy-
ogenesis. Indeed, the level of p-SMAD1/5 at day 3 in KO cells is significantly elevated as compared to WT cells, 
which is in line with the conclusion that SMURF1 negatively regulates SMAD1/5 signaling in P19.CL6 cells and 
when depleted from the cells enhances this signaling to increase the rate of cardiomyogenesis. Since SMAD1/5 
is activated by ligands of the BMP family, we next evaluated the effect of BMP2 stimulation on p-SMAD1/5 in 
both pluripotent cells and in cells subjected to cardiac lineage commitment by DMSO treatment. In both cases, 
BMP2-mediated phosphorylation of SMAD1/5 was significantly elevated in KO cells compared to WT cells after 
10 minutes of stimulation (Fig. 5B,C) as well as in undifferentiated KO cells after 30 minutes (Fig. 5B). These 
results support the conclusion that SMURF1 negatively regulates BMP2-mediated activation of SMAD1/5 during 
cardiomyogenesis.
To further evaluate the potential role of SMURF1 in regulating BMP signaling at the primary cilium, we ini-
tially performed IFM analysis on the localization of SMURF1 and BMP signaling components in cultures of RPE 
cells, which represent a well-established cell model system for ciliary signaling48–50. We found that both SMURF1 
and the BMP Receptors BMP-RI and BMP-RII localize at the primary cilium in these cells (Fig. 5D,E), and that 
siRNA-mediated knock-down of SMURF1 (Fig. 5F,G) is associated with an increased level of p-SMAD1/5 at the 
cilium in un-stimulated cells (Fig. 5H). These results support the conclusion that the primary cilium contains 
the complement of signaling modules required for regulating the balanced output of BMP-SMAD1/5 signaling. 
To address this in the context of in vivo heart development, we performed IFM analysis on the localization of 
p-SMAD1/5 in sections from embryonic mice at E12.5. In WT embryos we observed that SMAD1/5 is phos-
phorylated predominantly at the base of primary cilia in most cell types of the developing heart, including cells 
located in the atrial wall, the ventricular trabeculae and the endocardial cushions (Fig. 5I). We also noticed that 
the ciliary p-SMAD1/5 levels varied between cells in different heart regions as well as between neighboring cells 
within the same tissue as presented in Fig. 5I. These results suggest that SMAD1/5 phosphorylation at the cilium 
is highly dynamic during heart development, and we speculate that the variation in ciliary p-SMAD1/5 levels 
Figure 4. Functional analysis of SMUR1 during cardiomyogenesis in mESCs. qRT-PCR of the relative 
expression of (A) TnnT2, (B) Tagln, (C) S100A4 and (D) Kdr in FHF and SHF cells with or without transient 
knockdown of Smurf1 n = 4 (E) qRT-PCR of the relative expression of Smurf1 in mixed FHF and SHF 
population 24 hours after transfection.
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Figure 5. SMURF1 regulates BMP signaling. (A) Representative image of SDS-PAGE and WB analysis of 
the level of phospho-SMAD1/5 (p-SMAD1/5) during differentiation in WT and KO P19.CL6 cells (n = 3). 
(B) Left panel: SDS-PAGE and WB analysis of p-SMAD1/5 in P19.CL6 cells differentiated to day three and 
stimulated with 200 ng/ml BMP2. Right panel: Quantification of the relative levels of p-SMAD1/5 presented 
in the left panel (n = 5). Paired t-test was used for statistical analyses *p < 0.05. (C) Left panel: SDS-PAGE 
and WB analysis of p-SMAD1/5 in un-differentiated P19.CL6 cells stimulated with 200 ng/ml BMP2. Right 
panel: Quantification of the relative levels of p-SMAD1/5 presented in the left panel (n = 3). Paired t-test was 
used for statistical analyses *p < 0.05. (D) Representative images from IFM analysis with 3D reconstruction 
and isosurface visualization on the localization of SMURF1 (green) to the primary cilium marked with anti-
acetylated α-tubulin (Ac-tub, red, arrows) in RPE cells. Nuclei were stained with DAPI (blue). Asterisks mark 
the ciliary base area. (E) Representative images from IFM analysis on the localization of BMP receptors I and 
II (BMP-RI and BMP-RII, respectively) (green) to primary cilia (red) in RPE cells. (F) SDS-PAGE and WB 
analysis on the efficiency of siRNA-mediated knock-down of SMURF1 (siSMURF1) in RPE cells. (G) IFM 
analysis confirming that SMURF1 is depleted from cells subjected to siSMURF1 and that antibody recognition 
of SMURF1 (green) at primary cilium (red) is specific. (H) Representative images from IFM analysis with 3D 
reconstruction and isosurface visualization of the level of p-SMAD1/5 (green) at the primary cilium (red) in 
Mock- and siSMURF1-treated RPE cells. p150glued and HPRT were used as loading controls. Original pictures 
of western blots are shown in Supplemental Fig. 5. (I) Representative images from IFM analysis of WT mouse 
embryonic hearts at E12.5. Phosphorylation of SMAD1/5 (p-SMAD1/5, green) at the base of the primary 
cilium (ARL13B, red) was observed in the atrial wall, ventricular trabeculae and endocardial cushions (EC). 
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in part could be associated with differential expression of SMURF1. However, this could not be investigated in 
the present work, since our SMURF1 antibodies did not work well in the mouse tissues. Finally, to address the 
role of SMURF1 in regulating the level of SMAD1/5 phosphorylation at the cilia in E12.5 mouse embryos, we 
performed IFM analysis to compare p-SMAD1/5 levels in WT and Smurf1−/− tissues with focus on cells in the 
area surrounding the pharyngeal arch arteries at the aortic sac, which in human embryonic hearts of the same 
developmental stage shows a very prominent level of SMURF1 expression (Fig. 1D and E). Our analysis showed 
that phosphorylated SMAD1/5 localizes to the base of cilia in both WT and Smurf1−/−embryos, but that level of 
p-SMAD1/5 appeared significantly higher in the mutant embryos (Fig. 5J,K). These results could suggest that 
SMURF1 operates, at least in part, at the primary cilium to regulate BMP-SMAD1/5 signaling during develop-
ment of the heart.
Discussion
The spatiotemporal expression of SMURF1 during human heart development suggests that SMURF1 plays a role 
in multiple aspects of heart development, including OFT septation and formation of SMC in great and coronary 
arteries. The observed expression of SMURF1 in many different cell types and in different subcellular compart-
ments further indicates multiple roles of the protein during embryonic heart development. The studies in P19.
CL6 cells and mESCs suggest that SMURF1 regulates cell-type specification during cardiomyogenesis possibly 
through the regulation of ciliary signaling events.
Cardiac septation is a complex process that requires strict regulation of signaling pathways, including TGFβ/
BMP signaling51,52. The expression pattern of SMURF1 in human embryonic hearts suggests that SMURF1 is 
involved in OFT septation. In SMURF1-dependent EMT/EndoMT, TGFβ or BMP receptors reside at tight junc-
tions in polarized epithelial/endothelial cells. The binding of ligand ties the receptor II (RII) kinase to the RI:PAR6 
complex allowing for RII-mediated phosphorylation of PAR6 and recruitment of SMURF1 to the cell membrane. 
The complex of PAR6 and SMURF1 targets RHOA for degradation resulting in dissolution of tight junctions and 
downstream EMT/EndoMT17,18,20. At 35 and 38 dpf, SMURF1 is localized to the membrane in OFT mesenchymal 
cells, which is in agreement with a general role of SMURF1 in regulating EMT/EndoMT and migration. Cardiac 
fibroblasts evolve from EMT processes during development53. In our mESC experiments, depletion of Smurf1 
results in decreased expression of the cardiac fibroblast marker S100A4 (Fig. 5)54,55. This reduction in cardiac 
fibroblasts might partly explain the delay in OFT septation we observed in Smurf1−/− embryos, although this 
requires further investigation.
BMP signaling has roles in addition to the induction of EndoMT during OFT septation, and BMP4 has been 
found to regulate proliferation and apoptosis in OFT cushions56. The ubiquitous expression of SMURF1 in the 
myocardial cells of the OFT suggest that SMURF1 may regulate the steady state levels of BMP and TGFβ signaling 
components during OFT septation. SMURF1 is also expressed in the CNC-derived condensed mesenchyme in 
the OFT, as well as in the distal part of the OFT, suggesting that SMURF1 has a function in CNC-mediated OFT 
septation. In support of this, disruption of Smurf1 function in Xenopus embryos results in perturbed expression 
of the CNC marker slug14, SMURF proteins are important for CE movements in mice13, and Smurf1 is expressed 
in pharyngeal arch four in Xenopus embryos9,15. Furthermore, SMURF1 is important for cell migration and 
EMT17,18,20, processes that are important during CNC delamination and migration57. Whether SMURF1 has a 
function during CNC delamination and migration, however, requires further investigation. The localization of 
SMURF1 in the OFT of human embryos, nonetheless, prompted us to investigate if Smurf1−/− mouse embryos 
had defects in the OFT. We found that Smurf1−/− mouse embryos at developmental stage E12.5 display delayed 
septation of the OFT. The Smurf1−/− mice were in general smaller than their WT littermates, reminiscent of what 
was found in Xenopus morphants embryos11. Smurf1−/− mice are on the same somite stage as their WT littermates 
during development13, so the delay in OFT septation is not an indication of an overall developmental delay.
After OFT septation, SMURF1 is expressed in the SMCs of the coronary and great arteries. This could indi-
cate that SMURF1 is important for SMC differentiation. In agreement with this, low levels of BMP-dependent 
SMAD signaling is required during SMC proliferation58. SMURF1 is suggested to be involved in derivation of 
SMCs from the epicardium together with RHOA, PAR6 and TGFβ-RIII18, and Smurf1 is expressed in SMCs in 
rats59. Furthermore, SMURF1 has been shown to be involved in development of idiopathic pulmonary arterial 
hypertension (IPAH)59–61. Thus, multiple lines of evidence support a role of SMURF1 during SMC differentiation. 
In line with this, we observed a strong expression of SMURF1 in SMC of the coronary veins and great arteries. 
At 70 dpf SMURF1 expression is lost in the great arteries as well as in the coronary vessels, which suggests that 
SMURF1 is important only during differentiation of SMCs. This is in agreement with a requirement of a high 
level of BMP signaling when the SMC layer has formed to inhibit further proliferation of SMC. We observed a 
significant reduction of the SMC layer of the aorta in Smurf1−/− mice (Fig. 2C,D), supporting a role of SMURF1 
during SMC differentiation and/or proliferation. We note that the patient previously reported by Erdogan et al., 
carrying a 7p22 de novo duplication encompassing SMURF1, presented with coarctation of the aorta21. It is tempt-
ing to speculate that an increase in SMURF1 dosage may have caused dysregulation of SMC differentiation and/or 
proliferation during aortic development in this patient.
During the initial phases of heart development, SMURF1 is expressed in the myocardium, which inspired us 
to investigate the function of SMURF1 during cardiomyogenesis. We used the P19.CL6 cell line and mESC from 
(J) Representative images of the level of p-SMAD1/5 (green) at the base of the primary cilium (red) in cells 
surrounding the region of the pharyngeal arch arteries in WT and Smurf1−/− embryos. (K) Quantification 
of the arbitrary levels of p-SMAD1/5 at the ciliary base (n = 3). Paired t-test was used for statistical analyses 
**p < 0.01.
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FHF and SHF lineages. We utilized the CRISPR-Cas9 method to knock-out Smurf1 in P19.CL6 cells. We differ-
entiated the cells and showed that SMURF1 is a negative regulator of cardiomyogenesis. In the P19.CL6 cells, the 
activation of BMP signaling is vital for DMSO-induced cardiomyocyte differentiation62–64. As far as we are aware, 
however, the regulation of BMP signaling during differentiation has yet to be investigated. Using WB analysis, we 
found that the level of SMAD1/5 phosphorylation peaks around day 3 of differentiation, after which it declines. 
In the KO cells, this level was additionally increased compared to the WT cells. Following day 3, however, no 
apparent difference was observed, suggesting that SMURF1 regulates the level of SMAD1/5 phosphorylation in 
the initial phase of differentiation.
To support the data obtained from the P19.CL6 cells, we made a transient knockdown of Smurf1 in FHF 
and SHF cardiac progenitor cells followed by cardiac differentiation. The data show that, in SHF-derived cardi-
omyocytes, a knockdown of Smurf1 results in increased cardiomyogenesis, reminiscent of what we observed in 
the P19.CL6 cells. We did not, however, observe any significant effect from Smurf1 depletion on differentiation 
of FHF-derived cardiomyocytes. When we analyzed markers for different cell lineages, we observed that SMC 
and cardiac fibroblast markers were downregulated in SHF cells when Smurf1 was transiently depleted. These 
results suggest that SMURF1 regulates BMP signaling during cardiomyogenesis and that SMURF1 is important 
for cell-type specification.
Multiple signaling pathways that are regulated by SMURF1 play a critical role in heart development, includ-
ing TGFβ/BMP signaling33. These pathways have previously been shown to be coordinated by the primary cil-
ium to promote the differentiation of P19.CL6 cells into cardiomyocytes. Cardiomyogenesis is repressed in cells 
when the TGFβ pathway is blocked, or when formation of primary cilia is inhibited34,40. SMAD1/5 activation 
was increased in KO cells compared to WT cells at day 3 of differentiation. Further, to delineate how SMURF1 
regulates the BMP pathway, we applied BMP2 ligand to pluripotent cells, and to cells differentiated to day 3. 
We monitored pathway activation by the level of p-SMAD1/5. As expected, Smurf1 KO induced an increase in 
p-SMAD1/5 in both pluripotent and differentiated cells, which is in agreement with results obtained in other 
cell types9,23,35,36. To investigate whether SMURF1 functions at the primary cilium, we used cultures of RPE cells 
to show that SMURF1 as well as BMP receptors localize to the cilium and to the ciliary base region (Fig. 5D,E), 
which we previously showed plays a critical role in receptor-mediated endocytosis and SMAD2/3-dependent 
pathway activation40. In addition, siRNA-mediated depletion of SMURF1 in RPE cells led to an increased level 
of p-SMAD1/5 at the primary cilium in the absence of exogenously added BMP ligand (Fig. 5H), supporting 
the conclusion that SMURF1 operates at the cilium to modulate the basic level of SMAD1/5 activation. IFM 
analysis of sections from E12.5 mouse embryos shows that phosphorylated SMAD1/5 is predominantly located 
at the base of the primary cilium throughout the heart. In Smurf1−/− embryos we observed significant increase 
of SMAD1/5 phosphorylation at the pharyngeal arch arteries, a region where SMURF1 is strongly expressed at 
this stage in human embryos. Thus, our results suggest that SMURF1 regulates BMP signaling in the developing 
heart. However, these results should be interpreted with some caution. First of all, we observed differences in the 
developmental stage of the outflow tract between mutant and WT mice, thus the tissue we were comparing may 
have been at different stages of development. Secondly, the location of the pharyngeal arch arteries was deter-
mined from DAPI stained sections which may be imprecise. Third, we were not able to determine expression of 
SMURF1 in the mouse sections due to lack of functional antibodies. Nevertheless, these are the first data to show 
that SMURF1 localizes to the primary cilium and affects the level of p-Smad1/5 at the cilium in vitro and in vivo.
In summary, our study provides evidence that SMURF1 participates in development of the cardiac myocar-
dium, OFT, and blood vessels, in part by regulation of BMP signaling at the primary cilium. Future studies should 
focus on the role of SMURF1 during CNC migration, and how SMURF1 contributes to the regulation of the 
balanced and temporal activation and/or deactivation of cellular signaling events at the primary cilium during 
heart development.
Methods
Tissue samples. Human embryonic and fetal heart tissue samples were collected from spontaneous and 
legal induced abortions. Informed consent was obtained from all contributing women following oral and written 
information, in accordance with the Helsinki declaration II, and approved by the Research Ethics Committee 
of the Capital Region (KF–V.100.1735/90). The age of the embryo was based on measurement of crown-rump 
length. Following dissection, the samples intended for RNA extraction were frozen in liquid nitrogen or treated 
with RNAlater (ThermoFisher Scientific, Waltham, USA) according to the manufacturer’s instructions. Mouse 
embryos were collected at E12.5 and E15.5 and fixed in Bouin’s fixatives or 4% paraformaldehyde. The Smurf1 
mouse line was generated in Jeff Wrana’s lab. Animal experiments were performed following the recommenda-
tions of the Canadian Council on Animal Care. All experimental protocols have been approved by the Animal 
Care Committee of The Toronto Centre for Phenogenomics, Toronto, Canada.
Immunohistochemistry and quantification of fluorescence. Tissue samples were dissected into 
appropriate tissue blocks and fixed for 12–24 hours at 4 °C in 10% neutral buffered formalin, 4% Formol-Calcium, 
or Lillie’s or Bouin’s fixatives. The specimens were dehydrated with graded alcohols, cleared in xylene, and 
embedded in paraffin. Serial sections, 3–5 μm thick, were cut in transverse, sagittal or horizontal planes and 
placed on silanized slides. Sections were deparaffinized and rehydrated in xylene followed by a series of graded 
alcohol in accordance with established procedures and representative sections were stained with hematoxylin 
and eosin (HE). For bright field immunohistochemistry, sections were treated with 0.5% H2O2 for 15 minutes, 
blocked in 10% goat serum and incubated with primary antibodies followed by secondary antibodies (REAL 
EnVision Detection System, Peroxidase/DAB [Dako, Agilent Santa Clara, USA]). The sections were dehy-
drated in graded alcohols prior to mounting and slides were scanned using a panoramic desk II scanner from 
3DHISTECH (Budapest, Hungary). The images were processed using Panoramic Viewer (3DHISTECH). For 
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immunofluorescence microscopy, sections were deparaffinized as described above, treated with TEG buffer 
before blocking with Dako REALTM Antibody Diluent (Agilent, Santa Clara, USA) and left in primary antibod-
ies overnight at 4 °C in a humidified chamber. After PBS washing steps, cells were incubated in corresponding 
Alexa Flour® secondary antibodies for 45 min at room temperature. Cell nuclei were labeled by DAPI staining. 
Coverslips were mounted with either Dako fluorescent mounting medium or with PBS containing 90% glycerol, 
and 2% N-propyl-gallate and subjected to either confocal or epifluorescence microscopy. Laser scanning confocal 
microscopy images were captured using a Carl Zeiss LSM 780 microscope and analyzed throughout the z-axis of 
the section. Individual optical sections were stored as TIFF files using Zeiss ZEN Vision v10 (Zeiss, Oberkochen, 
Germany) and images were processed using ImageJ software65. Epifluorescence microscopy images were cap-
tured on a fully motorized Olympus BX63 upright microscope with an Olympus DP72 color, 12.8-megapixel, 
4.140 × 3.096-resolution camera and with a fully motorized and automated Olympus IX83 Inverted microscope 
with a Hamamatsu ORCA-Flash 4.0 camera (C11440-22CU). The software used was Olympus CellSens dimen-
sion, which was able to do deconvolution on captured z stacks, and images were processed for publication using 
Adobe Photoshop CS6. For quantification of levels of phospho-SMAD1/5 at the ciliary base, a circular outline 
was drawn around each base and using the measurement and region of interest (ROI)-function in the CellSens 
dimension software (Olympus) the Mean Green Fluorescence Intensity was measured in this area.
Cell cultures. P19.CL6 cells were cultured as previously described34,40. For differentiation experiments 4,000 
cells/cm2 were seeded in Petri dishes with MEM-alpha medium containing 1% DMSO to induce cardiomyo-
genesis. Differentiating cells were kept at 37 °C, 5% CO2 and 95% humidity, and medium was changed every 
second or third day. For stimulation experiments cells were seeded at a density of 17,000 cells/cm2. For overex-
pression studies 2 × 106 cells were electroporated with 1 ng plasmid using the NucleofectorTM 2b device from 
Axama (Lonza, Basel Switzerland) as previously described66. After electroporation cells were seeded at a density 
of 4,500 cells/cm2 to account for the cell death caused by transfection. HEK-293 cells were cultured in DMEM 
1965 medium supplemented with NaHCO3, Hepes, glutamax, antibiotics and FBS, and kept under incubator 
conditions as described above. The cells were passaged every second day. Immortalized human retinal pigment 
epithelial (hTERT-RPE1/RPE) cells were cultured to 80% confluency and then serum depleted for 24 hours to 
induce growth arrest and formation of primary cilia as previously described48. Mouse Embryonic Stem (mES) 
CellsIsl1−Cre; Ai9; Nkx2.5−GFP were derived from mice harboring Isl1Cre; Ai9; Nkx2.5-GFP. ES cells were maintained 
on gelatin-coated dishes in maintenance medium (Glasgow minimum essential medium with 10% fetal bovine 
serum and 1000 U/ml ESGRO (Millipore, Billerica, MA), Glutamax, sodium pyruvate and MEM non-essential 
amino acids (Life Technologies). Cardiac progenitor cells resembling heart field derivatives were induced with 
Activin A, BMP4, and VEGF (R&D Systems, Minneapolis, MN). After 5 days of differentiation, SHF and FHF 
cells were purified by Fluorescence-Activated Cell Sorting (FACS) (SH800, Sony Biotechnologies) based on their 
expression of GFP and/or RFP47.
Plasmids and oligonucleotides. For CRISPR-Cas9 genome editing a pCas9-GFP vector (hCas9, 9553 bp, 
plasmid 44719) and an empty sgRNA vector (gRNA_Cloning Vector, 3915 bp, plasmid 41824) were obtained 
from Addgene (Cambridge, MA, USA). Two sgRNAs for deletion of the Smurf1 gene were designed using 
CRISPR DESIGN (http://crispr.mit.edu/), and each sgRNA was cloned into the sgRNA vector using the protocol 
developed by Mali et al.67. Shortly, the sgRNAs were synthesized as 60-mer oligonucleotides (Suppl. Table 2) 
(Integrated DNA technologies, Coralville, IA). Double stranded 100 bp DNA fragments were generated using a 
Phusion® High-Fidelity DNA Polymerase kit [1 rxn: 10 μl Phusion reaction buffer (HF), 2.5 μl dNTP (10 mM), 
2 μl Smurf1_gRNA#1 F, and 2 μl Smurf1_gRNA#1 R, 2 μl Phusion DNA Polymerase, 31.5 μl ddH2O]. The dou-
ble stranded fragment was ligated into the sgRNA empty vector using the Gibson Assembly® Master Mix [5 μl 
(2×) Gibson assembly mix, 2 μl gRNA empty vector (linearized by AflII), 1 μl 100 bp PCR fragment, 2 μl ddH2O] 
and incubated at 50 °C (60 min). For overexpression of Smurf1, full length Smurf1 mouse cDNA cloned into 
pCMV-SPORT6 and was purchased from ImaGenes GmbH (now Source Bioscience, Nottingham, UK). An 
empty pCMV-SPORT6 vector was used for mock transfection. For transfection of RPE cells SMURF1 siRNA was 
obtained from Ambion (ID: s32796) (ThermoFisher Scientific).
Generation of mutant P19.CL6 cells. P19.CL6 cells were transfected with the two sgRNA-plasmids and 
the GFP-plasmid (6 ng each). After two days, the cells were sorted by FACS, and top 5% of GFP-positive cells was 
selected and transferred to MEM-alpha medium with serum and antibiotics. GFP-positive cells were seeded at a 
concentration of ~50 cells per ml to allow selection of single clones. DNA was isolated and amplified from a total 
of 66 clones, PCR products were separated using electrophoresis on a 2% agarose gel. Analysis of PCR products 
spanning the site of mutation suggested that 32 out of 66 cell clones (48%) were homozygous for the mutation, 23 
(35%) were heterozygous and 11 (17%) were homozygous for the normal Smurf1 allele (Suppl. Fig. 4B,C). Clones 
with a homozygous deletion or no deletion were selected for further analysis. Selected clones were genotyped by 
Sanger sequencing using primers spanning the CRISPR-Cas9 target site in Smurf1. Excess dNTPs and primers 
were removed before sequencing with exonuclease I (USB) and Shrimp alkaline phosphatase. Sequences were 
analyzed using CromasLite software edition 2.1.1 (Technelysium Pty Ltd, South Brisbane, Australia).
Knock-down by siRNA. RPE cells were cultured to 60% confluency prior to transfection with SMURF1 
siRNA or scrambled oligonucleotides (Mock) with similar GC content using DharmaFECT Duo (Dharmacon, 
Cat#T-2010-03) as previously described68. Twentyfour hours after transfection the medium was changed to serum 
deprived medium and the cells were cultured for 24 hours to induce growth arrest and formation of primary cilia. 
mESC were transfected with siRNA immediately after FACS sorting. Cells were transfected with Lipofectamine 
LTX or Lipofectamine 2000 (Life Technologies) in single-cell suspensions47.
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BMP signaling assays. For BMP2 signaling experiments in un-differentiated P19.CL6 cells, the medium 
was changed to medium without serum and antibiotics 24 hours prior to stimulation. Cells were stimulated with 
BMP2 (355-BM-050 R&D biosystems, Oxon, UK) at a final concentration of 200 ng/ml in medium without serum 
and antibiotics. When stimulating differentiated P19.CL6 cells, the cells were differentiated to day three, and new 
differentiation medium containing 200 ng/ml BMP2 was added to the cells. For both setups, cells were lysed in 1% 
SDS lysis-buffer at the indicated time points.
RNA extraction. Total RNA from human embryonic hearts was isolated using TRIzol Reagent. RNA from 
P19.CL6 cells was purified using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany) according 
to manufactures protocol, and stored at −80 °C. RNA samples from human adult hearts were obtained from 
Stratagene (San Diego USA) and Clontech (Mountain View, USA).
Real-Time Quantitative Reverse Transcription PCR qRT-PCR. RNA was reverse transcribed with a 
HT11V primer using SuperscriptII. Quantitative PCR analysis was carried out on an ABI 7500 Fast real-time 
PCR system using a LightCycler FastStart DNA MasterPLUS SYBR Green kit. All primer sets were designed to 
span at least one intron. Samples were run in duplicates and normalized to the average expression value of at least 
two housekeeping genes (for human samples: GAPDH, COX4 and ATP6 and for P19.CL6 samples: Psmd4 and 
Gapdh). Data from human samples were analyzed using the standard curve method and data from P19.CL6 cells 
were analyzed using the 2−ΔΔCT method69. Please see Suppl. Table 3 for primer sequences.
SDS-PAGE, Western Blotting and quantification of band intensities. P19.CL6 cells were lysed in 
1% SDS lysis-buffer and homogenized by sonication. Protein concentration was standardized using the BioRad 
DC Protein Assay. Proteins were resolved by gel electrophoresis on 10% bis-tris gels and run with NuPAGE MOPS 
SDS running buffer as previously described70. Proteins were subsequently electrophoretically transferred to nitro-
cellulose or PVDF membranes. The membranes were blocked with BSA or Odyssey® Blocking Buffer (Li-COR 
Biosciences, Lincoln, NE) and incubated with primary antibodies overnight. HRP-conjugated (Dako, Agilent) or 
IRDye® (Li-COR Biosciences) secondary antibodies were applied and the blots were developed using the ECLTM 
detection kit and FUSION-FX, or Odyssey® LCx imaging system (Li-COR Biosciences). Please see Suppl. Table 1 
for antibody specifications. For western blots (WB) shown in Fig. 3, the relative intensities were normalized to the 
loading control (p150glued) and band intensities were estimated from arbitrary densitometric values obtained with 
UNSCAN-IT version 5.1 software (Silk Scientific, Inc., Orem, Utah, USA). For WBs shown in Fig. 5, Image Studio 
lite version 5.2.5 (LICOR, Biosciences) was used to measure the intensities of the bands. All intensities of the 
loading control (HPRT) bands were divided with the highest HPRT intensity to get a relative normalized value. 
The band intensities of the protein of interest were divided by the relative HPRT value in their respective lane.
Immunocytochemistry. Cells were grown on glass coverslips, and fixed in 4% PFA and permeabilized in 
2% Triton X-100/PBS. 2% BSA was used for blocking and cells were incubated with primary antibodies fol-
lowed by incubation with Alexa flour® secondary antibodies (ThermoFisher Scientific). DAPI was used to mark 
nuclei. Immunofluorescence images were captured on a fully motorized Olympus BX63 upright microscope with 
a DP72 color, 12.8 megapixel camera and differential interference contrast (DIC). The software used was Olympus 
CellSens dimension, which is able to do 3D isosurface projections on captured z stacks. Image adjustments were 
carried out in Adobe Photoshop CS4 version 11.0. Please see Suppl. Table 1 for antibody specifications.
Flow cytometry. Cells were trypsinated, and 2 × 105 cells were fixed in 2% PFA for 20 min at room tempera-
ture. The cells were incubated with 5% goat serum with 0.5% Saponin. Cells were incubated with either α-actinin 
or control antibody with subsequent incubation with Alexaflour® secondary antibody. Cells were analyzed on 
a BD Accuri™ Flow Cytometer (BD Biosciences). Data was analyzed using the BD AccuriTM S6 Software (BD 
Biosciences).
Data availability statement. Data supporting the conclusions of this article are included in the article and 
supplementary files.
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